Contract manufacturing of biosimilars
By: Patti Seymour
IBC Life Science’s Biopharmaceutical Development and Production Week; 2013 Feb 25-Mar 1; Huntington Beach, CA
The global biosimilar market is estimated to grow to $170 billion by 2017. Many companies will be competing for a piece of this market so determining the overall demand and the corresponding manufacturing capacity required for biosimilars will be difficult. To minimize the risk of this capacity uncertainty, many biosimilar developers are outsourcing manufacturing. This presentation will explore the effect of biosimilar development on overall manufacturing capacity in both established and emerging markets.